Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques

• The Delta inactivated vaccine constructed in this study has high immunogenicity and good safety. • The inactivated vaccine has good cross-protection against SARS-CoV-2 variants. • The vaccine exhibited high productivity and good genetic stability in production.

Detalles Bibliográficos
Autores principales: Zhang, Yanjun, Mao, Haiyan, Li, Ju, Li, Jianhua, Huang, Chen, Li, Jiaxuan, Chu, Minglei, Xue, Fengbo, Wang, Linhui, Fang, Zhongbiao, Wang, Zhen, Wu, Jinan, Chen, Keda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wuhan Institute of Virology, Chinese Academy of Sciences 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212592/
https://www.ncbi.nlm.nih.gov/pubmed/37244519
http://dx.doi.org/10.1016/j.virs.2023.05.009
_version_ 1785047449542328320
author Zhang, Yanjun
Mao, Haiyan
Li, Ju
Li, Jianhua
Huang, Chen
Li, Jiaxuan
Chu, Minglei
Xue, Fengbo
Wang, Linhui
Fang, Zhongbiao
Wang, Zhen
Wu, Jinan
Chen, Keda
author_facet Zhang, Yanjun
Mao, Haiyan
Li, Ju
Li, Jianhua
Huang, Chen
Li, Jiaxuan
Chu, Minglei
Xue, Fengbo
Wang, Linhui
Fang, Zhongbiao
Wang, Zhen
Wu, Jinan
Chen, Keda
author_sort Zhang, Yanjun
collection PubMed
description • The Delta inactivated vaccine constructed in this study has high immunogenicity and good safety. • The inactivated vaccine has good cross-protection against SARS-CoV-2 variants. • The vaccine exhibited high productivity and good genetic stability in production.
format Online
Article
Text
id pubmed-10212592
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wuhan Institute of Virology, Chinese Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-102125922023-05-26 Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques Zhang, Yanjun Mao, Haiyan Li, Ju Li, Jianhua Huang, Chen Li, Jiaxuan Chu, Minglei Xue, Fengbo Wang, Linhui Fang, Zhongbiao Wang, Zhen Wu, Jinan Chen, Keda Virol Sin Letter • The Delta inactivated vaccine constructed in this study has high immunogenicity and good safety. • The inactivated vaccine has good cross-protection against SARS-CoV-2 variants. • The vaccine exhibited high productivity and good genetic stability in production. Wuhan Institute of Virology, Chinese Academy of Sciences 2023-05-25 /pmc/articles/PMC10212592/ /pubmed/37244519 http://dx.doi.org/10.1016/j.virs.2023.05.009 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter
Zhang, Yanjun
Mao, Haiyan
Li, Ju
Li, Jianhua
Huang, Chen
Li, Jiaxuan
Chu, Minglei
Xue, Fengbo
Wang, Linhui
Fang, Zhongbiao
Wang, Zhen
Wu, Jinan
Chen, Keda
Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
title Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
title_full Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
title_fullStr Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
title_full_unstemmed Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
title_short Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
title_sort delta (b.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to sars-cov-2 and circulating variants in rhesus macaques
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212592/
https://www.ncbi.nlm.nih.gov/pubmed/37244519
http://dx.doi.org/10.1016/j.virs.2023.05.009
work_keys_str_mv AT zhangyanjun deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT maohaiyan deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT liju deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT lijianhua deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT huangchen deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT lijiaxuan deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT chuminglei deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT xuefengbo deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT wanglinhui deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT fangzhongbiao deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT wangzhen deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT wujinan deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques
AT chenkeda deltab16172inactivatedvaccinecandidateelicitedneutralizingantibodiestosarscov2andcirculatingvariantsinrhesusmacaques

Ejemplares similares